International Journal of Antimicrobial Agents
Volume 36, Issue 2 , Pages 106-110 , August 2010

Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review

  • S. Kocher

      Affiliations

    • Research Unit for Neonatal Infectious Diseases and Epidemiology, Department of Pediatrics, Medical University of Graz, Austria
    • Division of Neonatology, Department of Pediatrics, Medical University of Graz, Austria
    • ,
  • W. Müller

      Affiliations

    • Research Unit for Neonatal Infectious Diseases and Epidemiology, Department of Pediatrics, Medical University of Graz, Austria
    • ,
  • B. Resch

      Affiliations

    • Research Unit for Neonatal Infectious Diseases and Epidemiology, Department of Pediatrics, Medical University of Graz, Austria
    • Division of Neonatology, Department of Pediatrics, Medical University of Graz, Austria
    • Corresponding Author InformationCorresponding author. Present address: Division of Neonatology, Department of Pediatrics, Medical University of Graz, Auenbruggerplatz 30, A-8036 Graz, Austria. Tel.: +43 316 385 2605; fax: +43 316 385 2678.

References 

  1. Sohn AH, Garret DO, Sinkowitz-Cochran RL, Grohskopf LA, Levine GL, Stover BH, et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey. J Pediatr. 2001;139:821–827
  2. Brodie SB, Sands KE, Gray JE, Parker RA, Goldmann DA, Davis RB, et al. Occurrence of nosocomial bloodstream infections in six neonatal intensive care units. Pediatr Infect Dis J. 2000;19:56–65
  3. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996;129:72–80
  4. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996;129:63–71
  5. Slee AM, Wuonola MA, McRipley RJ, Zajac I, Zawada MJ, Bartholomew PT, et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987;31:1791–1797
  6. Wise R, Andrews JM, Boswell FJ, Ashby JP. The in vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother. 1998;42:721–728
  7. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001;358:1975–1982
  8. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135–142
  9. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther. 2004;2:51–59
  10. Breha-Millet J, Calvet L, Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents. 2003;22:28–34
  11. Wallace RJ, Brown-Elliot BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001;45:764–767
  12. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci and selected Gram-negative organisms. Antimicrob Agents Chemother. 2003;47:1902–1906
  13. Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol. 1999;294:93–101
  14. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207–208
  15. Pharmacia & Upjohn Company. Zyvox: linezolid injection, linezolid tablets, linezolid for oral suspension package insert. Kalamazoo, MI: Pharmacia & Upjohn Company; 2002.
  16. Kearns GL, Jungbluth GL, Abdel-Rahman SM, Hopkins NK, Welshman IR, Grzebyk RP, et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther. 2003;74:413–422
  17. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J. 2003;22:677–685
  18. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates. Pediatr Infect Dis J. 2003;22(9 Suppl.):S158–S163
  19. Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J. 2003;22(9 Suppl.):S186–S192
  20. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J. 2002;21:798–799
  21. Kumar S, Kohlhoff S, Valencia G, Hammerschlag MR, Sharma R. Treatment of vancomycin-resistant Enterococcus faecium ventriculitis in a neonate. Int J Antimicrob Agents. 2007;29:740–741
  22. Langgartner M, Mutenthaler A, Haiden N, Pollak A, Berger A. Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2008;93:F397
  23. Ang JY, Luna JL, Turner DR, Asmar BI. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J. 2003;22:1101–1102
  24. Sung TJ, Kim HM, Kim MJ. Methicillin-resistant Staphylococcus aureus endocarditis in an extremely low-birth-weight infant treated with linezolid. Clin Pediatr (Phila). 2008;47:504–506
  25. Groll AH, Hoehn R, Schaefer V, Bauer K, Schloesser RL. Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates. Int J Antimicrob Agents. 2006;27:256–258
  26. Klingkowski U, Huth RG, Habermehl P, Knuf M. Linezolid in two premature babies with necrotizing enterocolitis and infection with vancomycin-resistant Enterococcus. Klin Padiatr. 2004;216:21–23[in German]
  27. Ng PC, Chow VC, Lee CH, Ling JM, Wong HL, Chan RC. Persistent Staphylococcus capitis septicemia in a preterm infant. Pediatr Infect Dis J. 2006;25:652–654
  28. Jungbluth GL, Welshman IR, Hopkins NK, Bruss JB, Wu E, Kearns GL. Impact of gestational and postnatal age on linezolid disposition in neonates and young infants. Pediatr Res. 2002;51:464A;[Abstract no. 2712]
  29. Kearns GL, Abdel-Rahman SM, Blumer JL, Reed MD, James LP, Jacobs RF, et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J. 2000;19:1178–1184[Erratum. Pediatr Infect Dis J 2001;20:732]
  30. Leeder JS, Kearns GL. Pharmacogenetics in paediatrics. Implications for practice. Pediatr Clin North Am. 1997;44:55–77
  31. Biedenbach DJ, Jones RN. Disk diffusion test interpretative criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. J Clin Microbiol. 1997;35:3198–3202
  32. Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis. 2001;20:432–434

PII: S0924-8579(10)00193-7

doi: 10.1016/j.ijantimicag.2010.03.030

International Journal of Antimicrobial Agents
Volume 36, Issue 2 , Pages 106-110 , August 2010

Article Tools

* Image Usage & Resolution